• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Topamax (topiramate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Topamax (topiramate)

  • Profile

Profile

Contact Information

Contact: Janssen
Website: https://www.topamax.com/

Currently Enrolling Trials

    Show More

    General Information

    Topamax (topiramate) has been approved as a new antiepileptic drug proven to reduce the frequency of seizures, particularly among patients who are not controlled by other antiepileptic drugs (AEDs). Topamax is indicated as adjunctive therapy for partial onset seizures, the most common seizure type, in adults.

    Therapy should be initiated at a low dose of 50 mg per day and gradually increased to an effective dose. The recommended daily dose is 400 mg per day in two divided doses.

    A new use for the anti-epileptic drug, Topamax (topiramate) has been approved by the FDA. This new use is as an add-on treatment for pediatric patients (ages 2-16) who experience partial onset seizures. This is the first anti-epileptic drug to be approved for treatment of partial onset seizures in patients as young as two. Partial onset seizures can cause sensory distortion, uncontrolled movements and, in some cases, an altered, trance-like consciousness.

    Topamax is available as a tablet and in a capsule formulation that can be opened and sprinkled onto food for easy swallowing. The capsule also can be swallowed whole, offering patients greater flexibility.

    Clinical Results

    Topamax has been studied in more than 2,000 epilepsy subjects worldwide. Five placebo-controlled, double blind clinical trials with Topamax demonstrated consistent results in reducing the frequency of seizures. In one trial with 181 subjects, seizure frequency was reduced by at least half in 44 percent (vs. 18 percent for placebo) and at least 75 percent in 22 percent of subjects (vs. 18 percent for placebo) taking the recommended 400 mg per day. Once stabilized on Topamax, four percent of subjects were seizure free throughout the trial period; no subjects on placebo were free of seizures during the same trial period. Patients selected for the trial were being treated with traditional AEDs; their average seizure frequency was approximately 11 per month at the time they entered the trial.

    Partial onset seizures: In a double-blinded, randomized, placebo-controlled trial of 86 pediatric patients between the ages of two and 16, at 17 clinical sites, Topamax effectively reduced the frequency of partial onset seizures in this population. Pediatric patients who received Topamax as add-on therapy with baseline anti-epileptic drugs (AEDs) over the course of the 16-week trial experienced a 33% reduction in seizures, compared to 11% for placebo and baseline AEDs.

    Side Effects

    Clinical trials indicate that Topamax is generally well tolerated by subjects and has few clinically significant interactions with traditional AEDs. The most frequently reported side effects were related to the central nervous system, which is common for this class of drugs, such as difficulty concentrating, drowsiness, dizziness and coordination problems. Most side effects were mild to moderate in severity and usually disappeared over time. There was a 1.5 percent incidence of kidney stones; nearly 80 percent of patients experiencing stones continued Topamax therapy.

    In the pediatric trial, the most common side effects associated with Topamax as add-on therapy included excessive drowsiness, loss of appetite, fatigue, nervousness, difficulty with concentration/attention, weight decrease, aggressive reaction, and difficulty with memory.

    Approval Date: 1997-01-01
    Company Name: Janssen
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing